Table 2.

Treatment-related adverse events of all grades reported in >20% and of grade 3 or 4 reported in >5% of patients by age.

TRAE1, n (%)	SG						TPC
	<65 years (n = 209)			≥65 years (n = 49)			<65 years (n = 176)			≥65 years (n = 48)
	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4	All grades	Grade 3	Grade 4
Hematologic
Neutropenia2	134 (64)	76 (36)	34 (16)	29 (59)	12 (24)	10 (20)	75 (43)	30 (17)	25 (14)	21 (44)	15 (31)	4 (8)
Anemia3	63 (30)	13 (6)	0	26 (53)	7 (14)	0	40 (23)	8 (5)	0	14 (29)	3 (6)	0
Leukopenia4	33 (16)	19 (9)	2 (1)	8 (16)	4 (8)	1 (2)	18 (10)	8 (5)	2 (1)	7 (15)	2 (4)	0
Febrile neutropenia	11 (5)	10 (5)	1 (<1)	4 (8)	2 (4)	2 (4)	5 (3)	4 (2)	1 (1)	0	0	0
Gastrointestinal
Diarrhea	121 (58)	22 (11)	0	32 (65)	5 (10)	0	20 (11)	1 (1)	0	7 (15)	0	0
Nausea	123 (59)	6 (3)	1 (<1)	24 (49)	0	0	48 (27)	0	0	11 (23)	1 (2)	0
Constipation	32 (15)	0	0	12 (24)	0	0	27 (15)	0	0	5 (10)	0	0
Vomiting	63 (30)	2 (1)	1 (<1)	12 (24)	0	0	20 (11)	0	0	3 (6)	1 (2)	0
Other
Fatigue	91 (44)	6 (3)	0	24 (49)	2 (4)	0	49 (28)	10 (6)	0	19 (40)	2 (4)	0
Alopecia	101 (48)	0	0	18 (37)	0	0	27 (15)	0	0	8 (17)	0	0
Decreased appetite	40 (19)	2 (1)	0	11 (22)	2 (4)	0	25 (14)	1 (1)	0	7 (15)	0	0

AE adverse event, MedDRA Medical Dictionary for Regulatory Activities, NCI CTCAE National Cancer Institute Common Terminology Criteria for AE, SG sacituzumab govitecan, TPC treatment of physician’s choice, TRAE treatment-related AE.

¹Patients may report more than 1 event per preferred term. AEs were coded using MedDRA v22.1, and AE severity was graded per NCI CTCAE v4.03.

²Combined preferred terms of “neutropenia” and “neutrophil count decreased.”

³Combined preferred terms of “anemia”, “hemoglobin decreased”, and “red blood cell count decreased.”

⁴Combined preferred terms of “leukopenia” and “white blood cell count decreased.”